社区

NEW YORK, Oct. 1, 2024 /PRNewswire/ -- Betters Medical Investment Holdings Limited ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider in China (which has recently expanded into the U.S. market following its receipt of US FDA 510(k) clearances), and ExcelFin Acquisition Corp. ("ExcelFin") (NASDAQ: XFIN), a publicly traded special purpose acquisition company, today announced the completion of their previously announced business combination (the "Business Combination"). The listed company resulting from the Business Combination is Baird Medical Investment Holdings Limited ("PubCo"), and its shares and warrants will commence trading on the Nasdaq under the ticker symbols "BDMD" and "BDMDW", respectively, on October 2, 2024.

美国纽约时间，2024年10月1日美通社发布——百德医疗投资控股有限公司(“Baird Medical”“百德医疗”或“公司”)是中国领先的微波消融(“MWA”)医疗设备开发商和供应商(最近在获得美国FDA 510(k)许可后扩展到美国市场)，以及ExcelFin Acquisition Corp.(NASDAQ:XFIN)，今天宣布完成其先前宣布的业务合并(“业务合并”)。合并后的上市公司是百德医疗投资控股有限公司(“PubCo”)，其股票和认股权证将于2024年10月2日在纳斯达克开始交易，股票代码分别为“BDMD”和“BDMDW”。

On September 26, 2024, ExcelFin held a special meeting of its stockholders (the "Special Meeting") to consider and vote upon a proposal to approve the Business Combination described in the proxy statement/prospectus. At the Special Meeting, in person or by proxy, the holders of 6,015,236 shares of ExcelFin's Class A common stock, constituting 91.36% of the issued and outstanding voting capital stock of ExcelFin entitled to vote, were present at the Special Meeting. Approximately 99.9% of the votes cast at the Special Meeting were in favor of approving the Business Combination. Complete official results of the vote are included in a current report on Form 8-K filed by ExcelFin with the U.S. Securities and Exchange Commission (the "SEC").

2024年9月26日，ExcelFin召开了股东特别会议(“特别会议”)，审议并投票批准委托书/招股说明书中所述的业务合并提案。在特别会议上，持有ExcelFin 6,015,236股A类普通股(占ExcelFin有投票权的已发行和已发行有表决权股本的91.36%)的股东亲自或通过代理人出席了特别会议。在特别会议上，大约99.9%的投票赞成批准企业合并。完整的官方投票结果包含在ExcelFin向美国证券交易委员会(SEC)提交的表格8-K的最新报告中。

Upon completion of the Business Combination, founders of Baird Medical and Grand Fortune Capital, LLC, co-sponsor of ExcelFin Acquisition Corporation, subscribed to a $4,900,000 Convertible Preferred investment in the Company.

在业务合并完成后，百德医疗的创始人和ExcelFin收购公司的共同发起人Grand Fortune Capital, LLC认购了该公司4,900,000美元的可转换优先股投资。

About Baird Medical

关于百德医疗

Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading microwave ablation ("MWA") medical device manufacturer and provider in China (and a recent entrant to the United States market). Baird Medical's proprietary medical devices are used for the treatment of benign and malignant tumors including thyroid nodules, liver cancer, lung cancer and breast lumps. Baird Medical is the first company to obtain a Class III medical devices registration certificate for MWA medical devices specifically indicated for thyroid nodules in China. For more information, please visit http://www.bairdmed.com/.

百德医疗成立于2012年，总部位于中国广州，是中国领先的微波消融(“MWA”)医疗设备制造商和供应商，并已成功进入美国市场。百德医疗的专利医疗设备用于治疗良性和恶性肿瘤，包括甲状腺结节、肝癌、肺癌和乳房肿块。百德医疗是国内首家获得甲状腺结节专用MWA医疗器械三级医疗器械注册证的公司。欲了解更多信息，请访问http://www.bairdmed.com/。

About ExcelFin

关于ExcelFin

ExcelFin is a blank check company formed as a Delaware corporation for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. ExcelFin's sponsors include Grand Fortune Capital, LLC ("GFC") and Fin Venture Capital ("Fin"). GFC is an affiliate of an investment group that completed a series of significant M&A transactions and investments in FinTech, Technology, Media, and Telecommunications  and Healthcare. Fin is a private equity firm focused on FinTech software.

ExcelFin是一家成立于特拉华州的空白支票公司，其目的是与一家或多家企业进行合并、股份交换、资产收购、股份购买、重组或类似业务组合。ExcelFin的赞助商包括Grand Fortune Capital, LLC(“GFC”)和Fin Venture Capital(“Fin”)。GFC是一家投资集团的子公司，该集团在金融科技、科技、媒体、电信和医疗保健领域完成了一系列重要的并购交易和投资。Fin是一家专注于金融科技软件的私募股权公司。

Forward-Looking Statements

前瞻性陈述

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or ExcelFin's, Baird Medical's, PubCo's or Tycoon's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by ExcelFin and Baird Medical and their management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. None of PubCo, ExcelFin, or Baird Medical undertakes any duty to update these forward-looking statements.

本新闻稿包含的某些陈述并非历史事实，而是根据1995年《美国私人证券诉讼改革法案》安全港条款所作的前瞻性陈述。前瞻性陈述通常与未来事件或ExcelFin、Baird Medical、PubCo或Tycoon的未来财务或经营业绩有关。在某些情况下，您可以通过以下术语来识别前瞻性陈述:“可能”、“可能”、“应该”、“期望”、“打算”、“可能”、“将”、“估计”、“预期”、“相信”、“预算”、“预测”、“打算”、“计划”、“潜在”、“预测”、“潜在”或“继续”，或者这些术语的否定或它们的变化或类似术语。前瞻性陈述受风险、不确定性和其他因素影响，这些因素可能导致实际结果与此类前瞻性陈述所表达或暗示的内容存在重大差异。这些前瞻性陈述基于估计和假设，虽然ExcelFin和Baird Medical及其管理层认为这些估计和假设是合理的，但本质上是不确定的。新的风险和不确定因素可能不时出现，不可能预测所有风险和不确定因素。您不应过分依赖本新闻稿中的前瞻性陈述，这些陈述仅在其发布之日起发表，并通过参考本新闻稿中的警示性陈述来完全限定。PubCo、ExcelFin或Baird Medical均不承担更新这些前瞻性陈述的任何义务。

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) risks related to the consummation of the Transactions; (2) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (3) the inability to recognize the anticipated benefits of the Transactions; (4) unexpected costs resulting from the Transactions; (5) changes in general economic conditions; (6) regulatory conditions and developments; (7) changes in applicable laws or regulations; (8) the nature, cost and outcome of pending and future litigation and other legal proceedings, including any such proceedings related to the Transactions and instituted against PubCo, ExcelFin, Baird Medical or others; and (9) other risks and uncertainties from time to time described in the Registration Statement relating to the Transactions, including those listed under the section titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC.

实际结果可能与前瞻性陈述中表达或暗示的内容存在重大差异，这些因素包括但不限于:(1)与交易完成相关的风险;(2)百德医疗在中国或美国拓展业务可能无法成功的风险;(3)无法确认交易的预期利益;(4)因交易产生的意外费用;(五)总体经济状况的变化;(六)监管情况和发展情况;(七)适用法律、法规的变更;(8)未决和未来的诉讼和其他法律程序的性质、成本和结果，包括针对PubCo、ExcelFin、Baird Medical或其他方提起的与交易相关的任何此类诉讼;(9)注册声明中不时描述的与交易相关的其他风险和不确定性，包括其中“风险因素”一节中列出的风险和不确定性，以及ExcelFin向美国证券交易委员会提交的其他文件。

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by PubCo in connection with the Transactions. All subsequent written and oral forward-looking statements concerning ExcelFin, Baird Medical, PubCo or Tycoon, the Transactions described herein or other matters attributable to ExcelFin, Baird Medical, PubCo, Tycoon or any person acting on their behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Each of ExcelFin, Baird Medical, PubCo and Tycoon expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

上述因素列表并不是排他性的。有关这些和其他风险因素的其他信息包含在ExcelFin向SEC提交的最新文件中，以及上述由PubCo提交的与交易相关的注册声明中。随后所有关于ExcelFin、Baird Medical、PubCo或Tycoon的书面和口头前瞻性陈述、本文所述的交易或其他归属于ExcelFin、Baird Medical、PubCo、Tycoon或代表其行事的任何人的事项，均明确受到上述警告性陈述的全面限制。请读者不要过分依赖任何前瞻性陈述，这些陈述仅在发布日期之前发表。ExcelFin、Baird Medical、PubCo和Tycoon均明确否认任何义务或承诺公开发布对本文所含任何前瞻性陈述的任何更新或修订，以反映其对前瞻性陈述的期望的任何变化或任何陈述所依据的事件、条件或情况的任何变化。